Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Prostate Cancer Market Size Anticipated to Increase with a CAGR of 8.1% in the 7MM for the Study Period 2017-30

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

09 Jun, 2020, 14:10 GMT

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, June 9, 2020 /PRNewswire/ -- As per DelveInsight's analysis, Prostate Cancer Market Size in the 7MM is anticipated to grow in the coming decade owing to increasing prostate cancer prevalence, rich pipeline, incremental healthcare spending and over a dozen of pharma companies working to fuel the market growth.

DelveInsight has announced the addition of a new market research report - Prostate cancer Market Insight, Epidemiology and Market Forecast -2030 to its portfolio.

Key Highlights

  • The total Prostate Cancer prevalent cases in the 7MM were observed to be 6,742,385 in 2017, and are expected to increase during the study period (2017–2030).
  • The US accounted for the highest number of Prostate Cancer prevalent cases, which is expected to increase by 2030.
  • Among all the treatment modalities, Zytiga (abiraterone acetate) and Xtandi (enzalutamide) are the cornerstone treatments of mCRPC.
  • The overall Prostate Cancer Market Size in the 7MM is anticipated to increase by 2030 owing to positive results of investigational products and a robust pipeline.
  • Key companies like AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, and Merck Sharp & Dohme and several other investigating their key products for the management of prostate cancer.

Request for Sample Pages: https://www.delveinsight.com/sample-request/prostate-cancer-market

Disease Overview

A malignancy of the prostate gland, Prostate cancer is the fourth most commonly prevalent form of cancer globally and the third most prevalent form in the US.

Prostate Cancer Epidemiology

The epidemiology forecast model of Prostate Cancer for the 7MM is based on the analysis of the prevalent and diagnosed prevalent cases of prostate cancer. Latter is further segmented into prostate cancer cases by age, clinical stages at diagnosis, non-metastatic and metastatic cases of HSPC/CSPC, and CRPC, and treated pool of non-metastatic and metastatic HSPC/CSPC and CRPC.

The Prostate Cancer epidemiology for 7MM for the study period of 2017-30 is segmented into:

  • Age-Specific Cases of Prostate Cancer
  • Total Treated Cases of mHSPC/CSPC and CRPC
  • Total Non-Metastatic and Metastatic Cases of CSPC/HSPC and CRPC
  • Total Diagnosed Cases of Prostate Cancer
  • Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages
  • Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC

As per the DelveInsight's Prostate Cancer Market Report, Prostate cancer is frequently diagnosed among men of the age group 65–74 years. Most of the cases of clinical-stage wise Prostate Cancer were of localized stage that accounted approximately 60% of the total diagnosed prevalent cases of prostate cancer in 2017.

Prostate Cancer Market

Prostate Cancer Market has several treatment options available to treat this condition in the 7MM, such as Active surveillance, Radiation therapy, Radical Prostatectomy (RP), Hormone therapy, Chemotherapy, and Immunotherapy. Prostate Cancer Market comprises of Jevtana (cabazitaxel) in combination with prednisone, Zytiga in combination with prednisone, after or before docetaxel therapy for different forms of cancer.

Recently, at 54th virtual meeting of ASCO, the results from the study sponsored by Bayer evaluating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) demonstrated significantly improve overall survival (OS) compared to ADT alone, in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

Prostate Cancer has a high curable rate if detected early; despite considerable progress in the development of novel therapeutic interventions, the introduction of effective diagnostic still lags. Therefore, the establishment of better diagnostic tools is needed.

Among the 7MM countries, the highest market size of Prostate Cancer was occupied by the United States, followed by Germany in Europe and Japan in 2017.

The Prostate Cancer Market is segmented by Distribution of Prostate Cancer in 2017 and 2030, size of the market by types of prostate cancer, therapy wise market size of castrate-resistant prostate cancer (CRPC), and therapy wise market size of castration-sensitive prostate cancer (CSPC).

Prostate Cancer Marketed Drugs

  • Xofigo (radium Ra 223 dichloride): Bayer Health Care
  • Xtandi (Enzalutamide): Astellas Pharma
  • Prolia (denosumab): Amgen
  • Erleada (apalutamide): Janssen Pharmaceutical
  • Jevtana (Cabazitaxel): Sanofi
  • Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation

Prostate Cancer Emerging Drugs

  • Lynparza: Pre-registration
  • Rucaparib: Pre-registration
  • Opdivo (nivolumab): Phase III
  • 177Lu-PSMA-617: Phase III
  • Niraparib ± Abiraterone Acetate: Phase III
  • HC-1119 (Deuterated form of enzalutamide): Phase III
  • Ipatasertib (RG7440) + Abiraterone Acetate: Phase III
  • Talazoparib ± Enzalutamide: Phase III
  • ProstAtak (AdV-tk) + valacyclovir: Phase III
  • Relugolix: Phase III
  • Capivasertib: Phase II
  • Seviteronel: Phase II
  • PRX302 (topsalysin) Phase II
  • RV001: Phase II

At present, several companies have indulged themselves in initiating clinical trials that investigate new treatments options or studying how to use existing treatment options better.

The current developmental Prostate Cancer pipeline is very robust including late- phase diverse group of drug classes such as PARPi, PD-L1i, AKTi. Besides, a strong pipeline, uptake of potential emerging therapies with better clinical profile, specially targeting the mutations like PARP inhibitors (i.e. BRCA mutation) are major factors driving the Prostate Cancer Market forward. Furthermore, due to an increase in the demand for the better treatment due to the rising Prostate Cancer prevalence, rising geriatric population, incremental healthcare spending, and rising awareness of the disease are other market drivers behind the changing dynamics of the Prostate Cancer market that is anticipated to change by 2030.

Conclusively, the positive results of investigational products and a robust pipeline for Prostate Cancer will bring a positive ray of hope for a better treatment pattern in the market in the coming years. The current scenario also anticipates a positive shift in the market for a study period (2017–2030).

Click to know more about the report offerings: https://www.delveinsight.com/report-store/prostate-cancer-market

Scope of the Report

  • Market Segmentation: 7MM, By Geographies, By therapies
  • Geography Covered: The United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Study Period: 3-year historical and 11-year forecasted analysis
  • Companies Covered: AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, and Merck Sharp & Dohme and others.
  • Comparative Analysis: Comparative and conjoint analysis of emerging therapies.
  • Case Studies
  • KOL's Views 

Reason to purchase

  • Bespoke primary and secondary research
  • 24*7 post-sale customer support
  • Option for customizing and personalizing research reports as per needs

Table of Contents

1

Key Insights

2

Executive Summary of Prostate Cancer

3

SWOT Analysis of Prostate Cancer

4

Prostate Cancer Market Overview at a Glance

5

Prostate Cancer Disease Background and Overview

6

Prostate Cancer Diagnosis

7

Prostate Cancer Epidemiology and Patient Population

8

Country-wise Prostate Cancer Epidemiology

9

Current Prostate Cancer Treatment Practices

10

Guideline of Prostate Cancer

11

Unmet Needs of Prostate Cancer

12

Prostate Cancer Marketed Therapies

13

Prostate Cancer Emerging Therapies

14

Prostate Cancer Seven Major Market Analysis

15

7MM Prostate Cancer Market Size

16

Prostate Cancer Market Access and Reimbursement

17

Prostate Cancer Market Drivers

18

Prostate Cancer Market Barriers

19

Appendix

20

DelveInsight Capabilities

21

Disclaimer

23

About DelveInsight

Request for a WebEx demonstration of the report: https://www.delveinsight.com/report-store/prostate-cancer-market

Related Reports:

Metastatic Hormone Refractory Prostate Cancer- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight's "Metastatic Hormone Refractory Prostate Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Metastatic Hormone Refractory Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Hormone Refractory Prostate Cancer market trends in the 7MM.

Castrate-Sensitive Prostate Cancer (CSPC) - Market Insights, Epidemiology and Market Forecast – 2030

DelveInsight's 'Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the 7MM.

Castrate-resistant Prostate Cancer (CRPC) - Market Insights, Epidemiology and Market Forecast – 2030

DelveInsight's 'Castrate-resistant Prostate Cancer (CRPC) -Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the CRPC, historical and forecasted epidemiology as well as the CRPC market trends the 7MM.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Get in touch for customizable solutions.

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330
DelveInsight

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain....

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.